At InsightRX, we are dedicated to advancing the science of individualized medicine. Special patient populations like obese, elderly, pregnant, or critically ill patients, are often opportunities to improve population pharmacokinetic (popPK) models for clinical decision-making.
To that end, our team is pleased to announce the launch of a newly developed vancomycin model for adult patients undergoing continuous renal replacement therapy (CRRT) within InsightRX Nova — a significant advancement for a group long underserved by existing pharmacokinetic tools.
Using a data set of nearly 900 adult CRRT patients receiving vancomycin across 83 clinical sites, our Data Science team evaluated current population PK models and identified critical gaps in both predictive accuracy and clinical usability.
By leveraging InsightRX’s continuous learning framework, we developed and validated a new two-compartment popPK model on nearly 2,500 patients (with CRRT and non-CRRT patients), which was optimized to deliver precise vancomycin dosing assessments by using broadly available covariates such as fat-free mass, serum creatinine, and age. These variables are routinely collected in clinical care, which makes this model easier to use than some other hemodialysis models.
The newly developed model outperforms all other published CRRT models, including the Bae, Hui, Ghouti-Terki (GT), and modified Goti (mG) models, on a hold-out data set of 263 patients and marks a meaningful step forward for clinicians caring for patients on hemodialysis. We've also already included it in an update to our marquee InsightRX Gemini model auto-select feature, meaning clinical decision support for patients on renal replacement therapy is that much easier.
Following this extensive evaluation, InsightRX now recommends the new Tong CRRT model as the default for dosing vancomycin in adult patients receiving continuous renal replacement therapy.
Want to learn more? Read the full analysis below!
